Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years

Orr, K.E.; Gould, F.K.; Short, G.; Dark, John H.; Hilton, Colin J.; Corris, Paul; Freeman, R.

doi:10.1016/s0163-4453(94)91082-0

Cited by 52 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the prevalence of toxoplasma antibody in our study and also Vejdani and Gharavi et al studies, and according to the potential reactivation of the disease and transmission of infection from seropositive donors to seronegative recipients after renal transplantation, we suggest that both the recipient and the donor candidate for kidney transplantation should be routinely tested for IgM and IgG anti-toxoplasma antibodies before transplantation to avoid kidney donation from seropositive donor to seronegative recipient and to better follow-up of seropositive recipients for reactivation of latent tissue cysts following immunosuppressive treatments (12)(13)(14)(15)(16)(17)(18)(19).…”

Section: Disscusionmentioning

confidence: 82%

“…Immunosuppressive treatments could reactivate latent tissue cysts and turning solid organ transplant recipients into active toxoplasmosis (11)(12)(13)(14)(15). Toxoplasmosis has also been recognized as a potential donor-to-host transmission infection after solid organ transplantation mainly from seropositive heart transplant donors to seronegative recipients, as the myocardium is one of the sites were cysts of toxoplasma gondii are located (16)(17)(18).…”

Section: Disscusionmentioning

confidence: 99%

“…This approach is very important especially in countries like us which about half of all the healthy people (donors) and recipients have IgG anti-toxoplasma antibodies in the plasma and therefore if we don't perform above screening method, some of toxoplasma -negative recipients may be toxoplasma infected from toxoplasma -positive donor (12)(13)(14)(15)(16)(17)(18)(19).…”

Section: Disscusionmentioning

confidence: 99%

See 2 more Smart Citations

Do we Need to Screen Uremic Patients for Toxoplasmosis before Kidney Transplantation?

Mousavi

Faramarzi

2013

Shiraz E-Med J

View full text Add to dashboard Cite

Background: Toxoplasmosis can cause serious complications among persons with weakened immune systems and therefore in solid organ transplant patients. Objectives: The aim of the study was to evaluate the value of screening for toxoplasma antibody titers in the donors and recipients candidate for renal transplantation in Ahvaz city, Iran. Materials and Methods: In a cross sectional study from March 2010 to April 2012, we evaluated donors and recipients who referred to our kidney transplant center in Naft Hospital, Ahwaz, Iran.Routine pre transplante laboratory testes including liver function and toxoplasma IgG and IgM antibody were performed. Results: A total of 52 people, 30 donors (20 male and 10 Female) and 22 recipients (12 male and 10 female) were included in the study. Mean age of donors and recipients were 30.32 ± 6.75 years and 45.09 ± 10.57 years respectively. The marker of HBV and HCV infection were negative in 100% of recipients and donors. Toxoplasma IgG antibody was positive in 45.45 percent of recipients (N = 10) and 63.33 percent of donors (N = 19) but there was no statistically significant difference between them (P = 0 .057) and between males and females (P = 0.74). Toxoplasma IgM antibody was negative in 100 percent of recipients (N = 22) and 93.33 percent of donors (N = 28). Conclusions: According to seropositivity for toxoplasma infection in about half of donors and recipients candidate for kidney transplantation, we should perform screening for this infection to avoid kidney donation from seropositive donor to seronegative recipient.

show abstract

Section: Disscusionmentioning

confidence: 82%

Section: Disscusionmentioning

confidence: 99%

Section: Disscusionmentioning

confidence: 99%

See 1 more Smart Citation

Do we Need to Screen Uremic Patients for Toxoplasmosis before Kidney Transplantation?

Mousavi

Faramarzi

2013

Shiraz E-Med J

View full text Add to dashboard Cite

show abstract

“…It usually results from a mismatch between the serological Toxoplasma statuses of the donor and the recipient (seropositive donor to seronegative recipient) and the transplantation of a graft containing encysted Toxoplasma (16,19). Heart and heart-lung transplants carry the highest risk of Toxoplasma graft transmission to a seronegative recipient (32), which can be prevented by cotrimoxazole prophylaxis (25). In high-risk mismatched heart recipients, the efficacy and safety of cotrimoxazole has been established (2,18) at the same dose regimen commonly used to prevent P. jirovecii pneumonia, but trimethoprim-sulfamethoxazole (160 and 800 mg) three times a week is also effective (2,24).…”

Section: Discussionmentioning

confidence: 99%

Correlation of Parasite Load Determined by Quantitative PCR to Clinical Outcome in a Heart Transplant Patient with Disseminated Toxoplasmosis

et al. 2010

View full text Add to dashboard Cite

Disseminated toxoplasmosis is a life-threatening infection in transplant recipients, which results either from reactivation of latent infection or from organ-transmitted primary infection. Preventive measures and diagnostic screening methods differ between countries and are related to the seroprevalence of Toxoplasma spp. in the general population. Here we report a case of disseminated toxoplasmosis in a heart transplant recipient with previous immunity that occurred after cotrimoxazole prophylaxis for the prevention of Pneumocystis jirovecii pneumonia was stopped. Quantitative PCR proved useful for the diagnosis and monitoring of Toxoplasma infection. Decreasing parasitic burdens in sequential samples of cerebrospinal fluid, blood, and bronchoalveolar lavage fluid correlated with a favorable outcome and allowed modulation of the immunosuppressive drug regimen. The duration of anti-Toxoplasma treatment and the need for maintenance prophylaxis are discussed, as well as prophylaxis for solid-organ transplant recipients. Although a rare event in heart transplant recipients, Toxoplasma reactivation must be investigated promptly, since early treatment improves the prognosis.

show abstract

“…It is also suggested that the myocardium is one of the sites, which the cysts of Toxoplasma gondii are located and therefore the transmission of infection occurs after heart transplantation from seropositive donors to seronegative recipients (14). Transmission of infection from seropositive donors to seronegative recipients has been described infrequently after liver transplantation (15).…”

Section: Dear Editormentioning

confidence: 99%

Screen of Uremic Patients for Toxoplasmosis Before Kidney Transplantation

Hayati

Shayanpour

2015

Shiraz E-Med J

View full text Add to dashboard Cite

Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years

Cited by 52 publications

References 11 publications

Do we Need to Screen Uremic Patients for Toxoplasmosis before Kidney Transplantation?

Do we Need to Screen Uremic Patients for Toxoplasmosis before Kidney Transplantation?

Correlation of Parasite Load Determined by Quantitative PCR to Clinical Outcome in a Heart Transplant Patient with Disseminated Toxoplasmosis

Screen of Uremic Patients for Toxoplasmosis Before Kidney Transplantation

Contact Info

Product

Resources

About